Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Aripiprazole

Aliases
Abilify, Lu AF41155, OPC-14597
Name
ABILIFY
INN Name
ARIPIPRAZOLE
FDA Approved
Yes

16 clinical trials

40 organizations

27 indications

5 documents

Indication
Schizophrenia
Indication
Bipolar I Disorder
Indication
Attenuated Psychosis Syndrome
Indication
Depression
Indication
Major
Indication
Adverse Reaction
Indication
Lipid Metabolism Disorders
Indication
Diabetes
Indication
NAFLD
Indication
Psychosis
Indication
Major Depressive Disorder
Indication
Dementia
Indication
Mild Cognitive Impairment
Indication
Treatment-Refractory Depression
Indication
Late-life depression
Indication
Geriatric Depression
Indication
Sequestra
Indication
Anxiety
Indication
Treatment Resistant Schizophrenia
Indication
Bipolar Disorder
Indication
Alcohol use disorder
Indication
Alcohol abuse
Indication
Stimulant Use Disorder with Stimulant-Induced Psychotic Disorder (Diagnosis)
Indication
Stimulant Use Disorder
Indication
Pharmacotherapy
Indication
Trichotillomania
Indication
Dermatillomania
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia"
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase 1b, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of Aripiprazole Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder
Status: Completed, Estimated PCD: 2020-07-08
Clinical trial
A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia
Status: Completed
Clinical trial
The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT)
Status: Terminated, Estimated PCD: 2022-04-04
Clinical trial
VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II
Status: Withdrawn, Estimated PCD: 2023-10-27
Clinical trial
Open-label, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Aripiprazole vs Paliperidone/Risperidone Using Multi-omics Data in Patients With a First Episode Psychosis
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Real-life Assessment of Aripiprazole Long-acting Injection (Abilify Maintena) Combined With Brexpiprazole (Rexulti) in Schizophrenia: a Naturalistic Non-interventional Prospective Follow-up Study
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Effect of add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia With Metabolic Syndrome: A Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2023-11-30
Clinical trial
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Randomized Controlled Trial to Evaluate Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Status: Terminated, Estimated PCD: 2019-06-30
Document
DailyMed Label: ABILIFY
Organization
Rebel Distributors Corp.
Document
DailyMed Label: aripiprazole
Organization
NuCare Pharmaceuticals,Inc.
Organization
STAT RX USA LLC
Organization
OrchidPharma Inc
Organization
Macleods Pharmaceuticals Limited
Organization
Alembic Pharmaceuticals Inc.
Organization
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
Organization
Apotex Corp.
Organization
NorthStar RxLLC
Organization
Safecor Health, LLC
Document
DailyMed Label: Abilify Asimtufii
Organization
Quallent Pharmaceuticals Health LLC
Organization
Solco Healthcare U.S., LLC
Organization
Proficient Rx LP
Organization
Major Pharmaceuticals
Organization
Dr. Reddy's Laboratories Inc.
Organization
NCS HealthCare of KY, LLC dba Vangard Labs
Organization
XLCare Pharmaceuticals, Inc.
Document
DailyMed Label: Aripiprazole
Organization
A-S Medication Solutions
Organization
Bionpharma Inc.
Organization
Otsuka America Pharmaceutical, Inc.
Organization
VistaPharm, LLC
Organization
McKesson Corporation dba SKY Packaging
Organization
Direct_Rx
Organization
SQUARE PHARMACEUTICALS LIMITED
Organization
Amneal Pharmaceuticals LLC
Organization
Camber Pharmaceuticals, Inc.
Organization
ScieGen Pharmaceuticals Inc
Organization
Unichem Pharmaceuticals (USA), Inc.
Organization
Alembic Pharmaceuticals Limited
Organization
Preferred Pharmaceuticals Inc.
Organization
Prefferred Pharmaceuticals Inc.
Organization
Viona Pharmaceuticals Inc.
Organization
Aurobindo Pharma Limited
Organization
Zydus Pharmaceuticals USA Inc.
Organization
Lannett Company, Inc.
Organization
Zydus Lifesciences Limited
Organization
REMEDYREPACK INC.
Document
DailyMed Label: Aripiprazole
Organization
AvPAK
Organization
RPK Pharmaceuticals, Inc.
Organization
bryant ranch prepack